New GLP-1 Pills Coming in 2026–2027
The year 2026 marks a turning point for weight loss therapy in the United States. For the first time, patients can access oral GLP-1 medication pills that offer the same powerful weight management benefits as injections but with far greater convenience. These new pills are expected to reshape obesity treatment, making it more accessible and affordable for millions of Americans struggling with weight and related health issues.
The Arrival of Oral GLP-1 Pills
Novo Nordisk launched the Wegovy pill, oral semaglutide, in early January 2026. This once-daily tablet is the first and only FDA-approved oral GLP-1 for weight loss in adults. It is designed for people with obesity or who are overweight and have at least one weight-related medical condition. The approval was based on the OASIS 4 clinical trial, which showed an average weight loss of 13.6% over 64 weeks, compared to just 2.7% with a placebo.
Eli Lilly’s orforglipron is another highly anticipated oral GLP-1 pill. It’s expected to receive FDA approval in 2026 and may offer a non-peptide, once-daily alternative that can be taken without food restrictions. Both companies are racing to expand their oral offerings, with several other candidates in development for both weight loss and type 2 diabetes.
How These Pills Work
GLP-1 pills mimic a hormone called glucagon-like peptide-1, which regulates appetite and blood sugar. By activating GLP-1 receptors in the brain and gut, these medications help patients feel full sooner and eat less. The oral versions use special absorption enhancers to ensure the peptide reaches the bloodstream effectively, overcoming previous challenges with bioavailability.
Clinical Evidence and Benefits
The Wegovy pill’s approval was supported by robust clinical data. In the OASIS 4 trial, 28% of participants lost 20% or more of their body weight, compared to only 3% in the placebo group. The pill also improved cardiometabolic risk factors, including blood pressure and glycemic control. For patients with obesity and cardiovascular disease, Wegovy is also approved to reduce the risk of major adverse cardiovascular events.
Pricing and Accessibility
Oral GLP-1 pills are significantly more affordable than injectable versions. The Wegovy pill starts at $149 per month for the lowest dose, with higher doses up to $299 monthly. For comparison, injectable GLP-1s can cost over $1,000 per month. Cash-paying American patients can access the pill through direct-to-consumer platforms like TrumpRx, part of a government-backed initiative to lower costs.
Medicare coverage for GLP-1 medications is expanding. Starting in April 2026, Medicare will cover these drugs for beneficiaries with obesity and related comorbidities. However, coverage for weight loss alone will remain limited until at least July 2026, and only for those with qualifying conditions.
Comparison Table: New Oral GLP-1 Pills
| Drug Name | Company | Status (2026) | Key Features | Indication | Price (Monthly) | Medicare Coverage (2026) |
| Wegovy (oral) | Novo Nordisk | Available Jan 2026 | Once-daily, oral semaglutide | Obesity, CVD risk | $149–$299 | Yes (with comorbidity) |
| Orforglipron | Eli Lilly | Expected 2026 approval | Once-daily, non-peptide | Obesity, T2D | TBD | Expected (with comorbidity) |
| CagriSema (combo) | Novo Nordisk | Under FDA review | Weekly injection, combo drug | Obesity, T2D | TBD | TBD |
What This Means for American Patients
Oral GLP-1 pills offer a game-changing alternative for Americans who want to lose weight but dread weekly injections. The convenience and lower cost could dramatically increase access, especially for seniors and those with insurance. However, coverage restrictions mean not everyone will qualify for Medicare benefits, and out-of-pocket costs may still be high for some.
FDA Approval
The FDA’s approval of oral GLP-1 pills marks a major shift in obesity treatment. The agency cited strong evidence of efficacy and safety, including reduced cardiovascular risk. The Trump administration’s Medicare expansion will help lower costs for eligible seniors, though full coverage for weight loss alone is still limited. Ongoing monitoring and policy changes are expected as more oral options enter the US market.
Conclusion
Oral GLP-1 pills are revolutionizing weight loss therapy in the United States. With Wegovy and orforglipron leading the way, US patients now have more convenient and affordable options than ever before. While Medicare coverage is expanding, access may still be limited for some.
As more oral GLP-1s are approved, expect a wave of innovation and competition that will further drive down costs and improve outcomes for millions of Americans.
At the same time, physicians stress the importance of proper medical guidance to ensure safe and effective use. Long-term success will likely depend on combining these medications with sustainable lifestyle changes and ongoing care.
